JP2001520998A - インドールｓＰＬＡ２阻害剤のモルホリノ−Ｎ−エチルエステルプロドラッグ - Google Patents

インドールｓＰＬＡ２阻害剤のモルホリノ−Ｎ−エチルエステルプロドラッグ

Info

Publication number
JP2001520998A
JP2001520998A JP2000517717A JP2000517717A JP2001520998A JP 2001520998 A JP2001520998 A JP 2001520998A JP 2000517717 A JP2000517717 A JP 2000517717A JP 2000517717 A JP2000517717 A JP 2000517717A JP 2001520998 A JP2001520998 A JP 2001520998A
Authority
JP
Japan
Prior art keywords
arthritis
compound
methyl
syndrome
biphenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2000517717A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001520998A5 (enExample
Inventor
マイケル・ライル・デニー
ジョン・マイケル・モリン・ジュニア
ダニエル・ジョン・サル
ジェイソン・スコット・ソーヤー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of JP2001520998A publication Critical patent/JP2001520998A/ja
Publication of JP2001520998A5 publication Critical patent/JP2001520998A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
JP2000517717A 1997-10-27 1998-10-26 インドールｓＰＬＡ２阻害剤のモルホリノ−Ｎ−エチルエステルプロドラッグ Withdrawn JP2001520998A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6364697P 1997-10-27 1997-10-27
US60/063,646 1997-10-27
PCT/US1998/022679 WO1999021559A1 (en) 1997-10-27 1998-10-26 MORPHOLINO-N-ETHYL ESTER PRODRUGS OF INDOLE sPLA2 INHIBITORS

Publications (2)

Publication Number Publication Date
JP2001520998A true JP2001520998A (ja) 2001-11-06
JP2001520998A5 JP2001520998A5 (enExample) 2006-01-05

Family

ID=22050578

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000517717A Withdrawn JP2001520998A (ja) 1997-10-27 1998-10-26 インドールｓＰＬＡ２阻害剤のモルホリノ−Ｎ−エチルエステルプロドラッグ

Country Status (9)

Country Link
US (1) US6177426B1 (enExample)
EP (1) EP1039911B1 (enExample)
JP (1) JP2001520998A (enExample)
AT (1) ATE296286T1 (enExample)
AU (1) AU1200899A (enExample)
CA (1) CA2308443A1 (enExample)
DE (1) DE69830335T2 (enExample)
ES (1) ES2241178T3 (enExample)
WO (1) WO1999021559A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015527372A (ja) * 2012-08-22 2015-09-17 ゼノポート，インコーポレイティド 副作用を低減させるモノメチルフマレートおよびそのプロドラッグの投与方法
JP2018528220A (ja) * 2015-09-16 2018-09-27 ヤンセン ファーマシューティカルズ，インコーポレーテッド デングウイルス複製阻害剤としての一または二置換インドール誘導体

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1200899A (en) 1997-10-27 1999-05-17 Eli Lilly And Company Morpholino-n-ethyl ester prodrugs of indole spla2 inhibitors
US6274578B1 (en) 1999-04-20 2001-08-14 Eli Lilly And Company sPLA2 inhibitor ester
US6140327A (en) * 1999-05-12 2000-10-31 Eli Lilly And Company Morpholino-n-ethyl ester derivative of an indole sPLA2 inhibitor
DE60032774D1 (de) * 1999-07-19 2007-02-15 Lilly Co Eli Spla2 inhibitoren
US6706752B1 (en) 1999-07-19 2004-03-16 Eli Lilly And Company sPLA2 inhibitors
US6831095B1 (en) 1999-09-20 2004-12-14 Eli Lilly And Company Hydroxyfunctional amide 1h-indole derivatives active as sPLA2 inhibitors
DE60032254D1 (de) * 1999-09-20 2007-01-18 Lilly Co Eli Hydroxyfunktionelle amid-1h-indolderivate aktiv als spla2 inhibitoren
DE19962300A1 (de) * 1999-12-23 2001-06-28 Asta Medica Ag Substituierte N-Benzyl-Indol-3-yl-glyoxylsäure-Derivate mit Antitumorwirkung
EP1303262A2 (en) * 2000-07-14 2003-04-23 Eli Lilly And Company Use of a spla2 inhibitor for the treatment of sepsis
US20030124174A1 (en) * 2001-10-25 2003-07-03 Endo Pharmaceuticals, Inc Method for treating non-neuropathic pain
AUPS282602A0 (en) 2002-06-07 2002-06-27 Garvan Institute Of Medical Research Method of inhibiting cell proliferation
EP4008327A1 (en) 2009-04-29 2022-06-08 Amarin Pharmaceuticals Ireland Limited Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
US20140348915A9 (en) 2012-08-22 2014-11-27 Xenoport, Inc. Oral Dosage Forms of Methyl Hydrogen Fumarate and Prodrugs Thereof
US10179118B2 (en) 2013-03-24 2019-01-15 Arbor Pharmaceuticals, Llc Pharmaceutical compositions of dimethyl fumarate
US9421182B2 (en) 2013-06-21 2016-08-23 Xenoport, Inc. Cocrystals of dimethyl fumarate
US9416096B2 (en) 2013-09-06 2016-08-16 Xenoport, Inc. Crystalline forms of (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate, methods of synthesis and use
US9999672B2 (en) 2014-03-24 2018-06-19 Xenoport, Inc. Pharmaceutical compositions of fumaric acid esters
JOP20160086B1 (ar) 2015-05-08 2021-08-17 2 Katholieke Univ Leuven Ku Leuven Research And Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
CA3013407A1 (en) 2016-03-31 2017-10-05 Janssen Pharmaceuticals, Inc. Substituted indoline derivatives as dengue viral replication inhibitors
JOP20170069B1 (ar) 2016-04-01 2021-08-17 1 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20180026A1 (ar) 2017-03-31 2019-01-30 Univ Leuven Kath مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20180025B1 (ar) 2017-03-31 2021-08-17 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
EA201992782A1 (ru) 2017-05-22 2020-03-24 Янссен Фармасьютикалз, Инк. Замещенные производные индолина в качестве ингибиторов репликации вирусов денге
EA039702B1 (ru) 2017-05-22 2022-03-01 Янссен Фармасьютикалз, Инк. Замещенные производные индолина в качестве ингибиторов репликации вирусов денге

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE220394T1 (de) 1994-04-01 2002-07-15 Lilly Co Eli 1h-indol-3-glyoxylamid spla2 inhibitoren
US5972988A (en) 1997-03-26 1999-10-26 Eli Lilly And Company Method for treatment of chronic bronchitis using indole compounds
AU1200899A (en) 1997-10-27 1999-05-17 Eli Lilly And Company Morpholino-n-ethyl ester prodrugs of indole spla2 inhibitors
AU1200799A (en) * 1997-10-27 1999-05-17 Eli Lilly And Company Isopropyl ester prodrugs of indole spla2 inhibitors
CA2310249A1 (en) 1997-11-14 1999-05-27 August Masaru Watanabe Treatment for alzheimer's disease

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015527372A (ja) * 2012-08-22 2015-09-17 ゼノポート，インコーポレイティド 副作用を低減させるモノメチルフマレートおよびそのプロドラッグの投与方法
JP2018528220A (ja) * 2015-09-16 2018-09-27 ヤンセン ファーマシューティカルズ，インコーポレーテッド デングウイルス複製阻害剤としての一または二置換インドール誘導体
JP7050666B2 (ja) 2015-09-16 2022-04-08 ヤンセン ファーマシューティカルズ，インコーポレーテッド デングウイルス複製阻害剤としての一または二置換インドール誘導体

Also Published As

Publication number Publication date
ATE296286T1 (de) 2005-06-15
US6177426B1 (en) 2001-01-23
CA2308443A1 (en) 1999-05-06
WO1999021559A1 (en) 1999-05-06
EP1039911B1 (en) 2005-05-25
AU1200899A (en) 1999-05-17
EP1039911A1 (en) 2000-10-04
DE69830335T2 (de) 2006-02-02
EP1039911A4 (en) 2002-07-17
ES2241178T3 (es) 2005-10-16
DE69830335D1 (de) 2005-06-30

Similar Documents

Publication Publication Date Title
JP2001520998A (ja) インドールｓＰＬＡ２阻害剤のモルホリノ−Ｎ−エチルエステルプロドラッグ
JP5836995B2 (ja) アミノ酸のｎ−アシル誘導体、その製法、薬理組成物および抗−アレルギー性、抗−炎症性および抗−脂血性薬剤としてのその使用
BE1006343A5 (fr) Derives de l'indole.
AU688458B2 (en) 1H-indole-3-glyoxylamide sPLA2 inhibitors
EP1100492B1 (en) INDOLE sPLA2 INHIBITORS
JP2001520991A (ja) インドールｓＰＬＡ２阻害剤のＮ，Ｎ−ジエチルグリコールアミドエステルプロドラッグ
EP0753004A1 (en) Antagonists of endothelin receptors
JP2002522386A (ja) インドールｓＰＬＡ２インヒビター
JPH08253448A (ja) 複素環式置換基を有するオキシ−フエニル−（フエニル）グリシノールアミド
JP4564669B2 (ja) インドールｓＰＬＡ２インヒビターのモルホリノ−Ｎ−エチルエステル誘導体
JP2002513761A (ja) ｓＰＬＡ２阻害剤エステル
US6391908B1 (en) Oxime amide indole type sPLA2 inhibitors
WO1999021545A1 (en) ISOPROPYL ESTER PRODRUGS OF INDOLE sPLA2 INHIBITORS
JP2003505372A (ja) ｓＰＬＡ２インヒビター
EP1220839B1 (en) Hydroxyfunctional amide 1h-indole derivatives active as spla2 inhibitors
JPWO1998037069A1 (ja) インドール系ジカルボン酸誘導体

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050728

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050728

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20061018